Vipin K. Garg
Known title: President and CEOCIK: 0001515813
Associated companies
Transaction History
| ALT | ▲ Buy | Grant | 6,926 | $21K | 1/31/2026 | View on chart |
| ALT | ▲ Buy | Option Exercise | 26,775 | $0 | 1/30/2026 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 11,632 | $65K | 1/30/2026 | View on chart |
| ALT | ▲ Buy | Option Exercise | 41,200 | $0 | 1/27/2026 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 17,898 | $111K | 1/27/2026 | View on chart |
| ALT | ▲ Buy | Option Exercise | 42,050 | $0 | 1/25/2026 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 17,984 | $99K | 1/25/2026 | View on chart |
| ALT | ▲ Buy | Option Exercise | 18,950 | $0 | 2/2/2025 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 8,282 | $55K | 2/2/2025 | View on chart |
| ALT | ▲ Buy | Option Exercise | 16,545 | $0 | 2/1/2025 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 7,231 | $48K | 2/1/2025 | View on chart |
| ALT | ▲ Buy | Grant | 4,105 | $21K | 1/31/2025 | View on chart |
| ALT | ▲ Buy | Option Exercise | 26,775 | $0 | 1/30/2025 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 11,701 | $82K | 1/30/2025 | View on chart |
| ALT | ▲ Buy | Option Exercise | 42,050 | $0 | 1/25/2025 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 18,157 | $127K | 1/25/2025 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 8,376 | $78K | 2/2/2024 | View on chart |
| ALT | ▲ Buy | Option Exercise | 18,950 | $0 | 2/2/2024 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 7,313 | $72K | 2/1/2024 | View on chart |
| ALT | ▲ Buy | Option Exercise | 16,545 | $0 | 2/1/2024 | View on chart |
| ALT | ▲ Buy | Grant | 7,889 | $21K | 1/31/2024 | View on chart |
| ALT | ▲ Buy | Option Exercise | 26,775 | $0 | 1/30/2024 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 11,697 | $115K | 1/30/2024 | View on chart |
| ALT | ▲ Buy | Grant | 126 | $354 | 7/31/2023 | View on chart |
| ALT | ▲ Buy | Option Exercise | 18,950 | $0 | 2/2/2023 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 8,422 | $127K | 2/2/2023 | View on chart |
| ALT | ▲ Buy | Option Exercise | 16,546 | $0 | 2/1/2023 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 7,658 | $106K | 2/1/2023 | View on chart |
| ALT | ▲ Buy | Grant | 1,938 | $20K | 1/31/2023 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,007 | $30K | 11/30/2022 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,007 | $38K | 10/30/2022 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,008 | $38K | 9/30/2022 | View on chart |
| ALT | ▼ Sell | Open Market | 20,000 | $400K | 8/31/2022 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,007 | $57K | 8/30/2022 | View on chart |
| ALT | ▼ Sell | Open Market | 15,000 | $226K | 8/12/2022 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,007 | $36K | 7/30/2022 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,007 | $35K | 6/30/2022 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,008 | $15K | 5/30/2022 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,008 | $14K | 4/30/2022 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,007 | $18K | 3/30/2022 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,007 | $22K | 2/28/2022 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 7,655 | $61K | 2/1/2022 | View on chart |
| ALT | ▲ Buy | Option Exercise | 16,545 | $0 | 2/1/2022 | View on chart |
| ALT | ▲ Buy | Grant | 2,757 | $19K | 1/31/2022 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,355 | $17K | 1/30/2022 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,007 | $27K | 12/30/2021 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,007 | $32K | 11/30/2021 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,007 | $32K | 10/30/2021 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,007 | $34K | 9/30/2021 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,008 | $42K | 8/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Altimmune to attend Wells Fargo healthcare conference
Altimmune has been confirmed as a participant in the Wells Fargo 21st Annual Healthcare Conference. The company joins a roster of healthcare firms presenting at the event, which is a common venue for biopharma companies to engage with investors and outline pipeline progress. No new clinical, regulatory, or financial announcements accompanied the participation news, so the development is a routine scheduling item rather than a fundamental catalyst. As context, the stock has been trading well below the average analyst price target of $17.22, with its 52-week range between $2.56 and $6.44.
Altimmune to attend Wells Fargo healthcare conference. Altimmune has been confirmed as a participant in the Wells Fargo 21st Annual Healthcare Conference. The company joins a roster of healthcare firms presenting at the event, which is a common venue for biopharma companies to engage with investors and outline pipeline progress. No new clinical, regulatory, or financial announcements accompanied the participation news, so the development is a routine scheduling item rather than a fundamental catalyst. As context, the stock has been trading well below the average analyst price target of $17.22, with its 52-week range between $2.56 and $6.44.